Company Overview

Industry Sector: Drug Discovery, Infectious Disease Therapeutics

Company Overview: ioGenetics is an early stage company which was created by spin-off from another Founders’ company. It has achieved considerable progress in biotherapeutic technology development and has pioneered a novel antimicrobial platform called Directed Biocides™, distinct in structure and function from current antibiotics and anti-parasitic drugs. Directed Biocides™ are fusion protein molecules which employ a targeting component to direct an antimicrobial peptide or lytic enzyme to a specific pathogen, destroying the microbe and recruiting the host response.

Target Market(s): Anti-infectives/ antimicrobials for human and veterinary markets

Management

Leadership:
Jane Homan, Ph.D., MRCVS, Chief Executive Officer
Robert Bremel, Ph.D., Chief Scientific Officer
Michael Imboden, Ph.D., Director of R&D

Advisors:
Herman Van Cauteren, DVM, Pharmaparacelsus BVBA
Robert Woestenborghs, MSC, Pharmaparacelsus BVBA
Pierre Veys, DVM, Pharmaparacelsus BVBA
Michael Riggs, DVM, PhD, University of Arizona
Jorge Osorio, DVM, PhD, University of Wisconsin

Key Value Drivers

Technology*: ioGenetics’ lead therapeutic is an oral Directed Biocide™ for treating cryptosporidiosis, which affects both humans and animals.

Competitive Advantage: ioGenetics uses a “rational design” process to design and construct fusion proteins targeting a broad range of microorganisms. The time required from design to testing is short, and we can rapidly scale up production. Directed Biocides™ offer an alternative to traditional antibiotics and anti-parasitic drugs that have long discovery and development times.

Plan & Strategy: ioGenetics will design and develop antimicrobial fusion proteins, either directly with collaboration partners or with the goal of future out-licensing. ioGenetics is also developing therapeutics for neglected tropical diseases through federal grant and non-profit funding. Our anti-cryptosporidial therapeutic is in animal trials and will be commercialized first as an animal health product.

*Technology funded by the NIAID and being commercialized under the NIH-CAP

Antimicrobials in ioGenetics’ pipeline

- Design
- Expression
- Efficacy In vitro
- Efficacy in animals
- Scale up, Preclinical or Field Trials

Anticryptosporidial - C. parvum
Anticryptosporidial - C. hominis
Antibacterial MRSA
Antiviral Dengue, herpes, influenza
Antiprotozoal Entamoeba, Giardia, malaria